Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428427 · ClinicalTrials.gov registry record · Phase 1
Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01428427 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 31 participants.
The verdict
NCT01428427, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
MEK112111 is a dose-escalation, Phase IB, open-label, single-arm, multi-center study. The primary objective of the study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with gemcitabine in subjects with solid tumors.
Interventions
- DRUG Gemcitabine
- DRUG GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-08-12 |
| Est. Completion | 2011-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428427
The ClinicalTrials.gov registry entry for NCT01428427 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01428427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01428427 about?
NCT01428427 is a clinical study titled "Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors". MEK112111 is a dose-escalation, Phase IB, open-label, single-arm, multi-center study. The primary objective of the study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with gemcitabine in subjects with solid tumors.
What is the current status of trial NCT01428427?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-08-12. Estimated completion is 2011-07-18.
What interventions are being tested in trial NCT01428427?
The interventions under investigation include: Gemcitabine (DRUG), GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT01428427?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.